# Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma

> **NCT02659293** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **University of Chicago** · enrollment: 180 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Carfilzomib
- **DRUG:** Dexamethasone
- **DRUG:** Lenalidomide (Control)

## Key facts

- **NCT ID:** NCT02659293
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-04-26
- **Primary completion:** 2027-11
- **Final completion:** 2027-11
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02659293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02659293, "Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02659293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*